AstraZeneca's investigational GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against oral treatments already on the market.
Elaine Chen is a national biotech reporter at STAT and co-writes The Readout newsletter. She focuses on pharmaceutical manufacturing, regulation, and healthcare administration, drawing from her previous experience covering cardiovascular and metabolic diseases. Elaine's work has been featured in notable publications including BioRxiv, Yahoo Finance, and The New York Times.













